A previous prospective study of first-line gefitinib treatment for patients with advanced EGFR mutation (DEL, L858R, G719X or L861Q)-positive NSCLC without indication for cytotoxic chemotherapy as a result of poor PS has supported the use of EGFR-TKIs for these patients [15]. Here, EGFR is linked to non-small cell lung carcinoma.